Collaboration
In Cell Art, a specialist in the drug-delivery of siRNA, DNA and protein drugs, has expanded its research collaboration agreement with Sanofi Pasteur, the vaccines division of Sanofi Aventis Group. Under the agreement In Cell Art’s nanocarrier technologies will be evaluated for use in of Sanofi Pasteur’s vaccines programme.
“This agreement highlights [the potential of] In Cell Art’s nanocarrier technologies for new vaccine development,” said Chloé Bellocq, CEO, and Bruno Pitard, co-founder of In Cell Art.
The Nantes-based company’s ICA614 nanocarrier, formulated from synthetic DNA, features a dramatic enhancement of the immunogenicity of plasmid DNA-encoding tumour or pathogen-derived antigens, a reduction of the dose of plasmid DNA, and an excellent safety profile.
ICA614 is currently in use, or being tested, by other vaccine development companies, for use in DNA vaccines. It has also been shown to increase the immunogenicity of subunit vaccines.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
